8:20 am Chairperson’s Opening Remarks

  • Alain Beck Senior Director, Biologics CMC & Developability, Pierre Fabre

Showcasing Game-Changing ADCs With a View to Moving ADCs into Earlier Line Treatments to Improve Patient Outcomes Sooner

8:30 am Development of ENHERTU, An HER2-directed Dxd ADC, In Early Breast Cancer & Beyond

  • Gilles Gallant SVP Global Head, Oncology Department, Oncology R&D, Daiichi Sankyo


  • Discussing Destiny-Breast03, a Phase 3 randomised study of ENHERTU versus T-DM1 in patients with HER2+ metastatic breast cancer
  • Reviewing plans to develop ENHERTU in early breast cancer
  • Describing plans to expand the development of ENHERTU in gastric cancer, NSCLC and other tumours

9:00 am ADC Therapeutic Window Enhancement Based on the AJICAP Chemical Site-Specific Conjugation Platform

  • Zhala Tawfig Process Development & TT Associate Scientist, Ajinomoto Bio- Pharma Services


  • Examining how site-specific technologies are being employed in many of the next-generation ADCs due to enhancement of clinically-relevant biological properties observed in various preclinical studies
  • Demonstrating a novel method of affinity peptide mediated regiodivergent antibody functionalisation that enables the synthesis of ADCs from native IgGs in a tunable and atom-precise manner
  • Highlighting how both thiol-based and azide-based site-specific ADCs produced by “AJICAP” technology demonstrated an expansion of their therapeutic index compared with stochastic technology

9:30 am Exploring Tisotumab Vedotin in Frontline Cervical Cancer


  • Showcasing Tisotumab Vedotin data from the innovaTV 204 clinical trial
  • Discussing emerging Tisotumab Vedotin data as a frontline treatment
  • Exploring how Tisotumab Vedotin has the possibility as a frontline treatment for cervical cancer

10:00 am
Morning Break

1:00 pm
Lunch & Networking

Delving into the Development of Antibody Drug Conjugates with Novel Modes of Action

2:00 pm Antibody-mediated Delivery of Protein Degraders


  • Sharing efforts to expand ADC technology outside of pan-cytotoxics
  • Evaluating the impact of DAR and payload potency on ADC activity
  • Optimising linker-drug structure for PK

2:30 pm Modulating the Therapeutic Activity of ADCs & SMDCs With Engineered Cytokine Products


  • Understanding how the therapeutic activity of ADCs and SMDCs can be potentiated with certain antibody-cytokine fusion proteins
  • Illustrating how antibody-cytokine fusions, based on interleukin-2 and capable of selective localisation at the tumour site, are particularly effective in boosting the activity of ADCs and SMDCs
  • Discussing the role of NK cells and of T cells

3:00 pm Designing Immune-Stimulating Antibody Conjugates

  • Edith Perez Chief Medical Officer, Bolt Biotherapeutics


  • Overview of Bolt’s Immune-Stimulating Antibody Conjugates (ISAC) technology platform as the next step in ADC-based immune therapy
  • Highlighting the key features and the mechanism of action
  • Demonstrating the use of various methods to understand and design potent ISACs

3:30 pm
Afternoon Refreshments

Analysing Innovative Technologies to Progress the Next Generation of ADCs

4:00 pm Novel In Vitro Screening Assays for ADC Characterisation & Stability Assessment


  • Exploring new approaches to characterise ADCs In Vitro
  • Outlining how this technology can be leveraged to design best-in-class ADCS

4:30 pm Bicycle Conjugates to Target Solid Tumours

  • Gavin Bennett Senior Director - Drug Development, Bicycle Therapeutics


  • Bicycles, constrained bicyclic peptides, offer antibody-like affinity and selectivity in a small molecule format
  • Bicycle Toxin Conjugates are now in clinical development, offering rapid tumour penetration with limited plasma exposure
  • Discover how Bicycles can be used to stimulate Immuno-oncology targets such as CD137, which can be targeted to tumour cells using Bicycle tumour-targeted immune cell agonising molecules (TICAs™)

5:00 pm End of Scientific Programme Day Two